Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mariana Kulynych-Miskiv (Galych, Ukraine), Mariana Kulynych-Miskiv, Mykola Ostrovskyy, Iryna Savelikhina, Oleksandr Varunkiv, Kseniia Ostrovska. Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis. Eur Respir J 2016; 48: Suppl. 60, 4099

Member's Comments

No comment yet.

Related content which might interest you: Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD Source: International Congress 2014 – Markers Year: 2014 Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Impact of mucolytic treatment on COPD exacerbations Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment Source: International Congress 2016 – Translational studies in lung disease Year: 2016 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Estimation of tiotropium efficacy at the COPD patients with group D Source: International Congress 2015 – Different data in COPD Year: 2015 A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations Source: International Congress 2015 – Latest insights into chronic care Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The effect of tiotropium bromide on lung function parameters in patients with asthma- COPD overlap syndrome Source: International Congress 2016 – Asthma points to ponder Year: 2016 The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS Source: International Congress 2014 – COPD exacerbations Year: 2014 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Changes of TNF-a level in bronchoalveolar fluid of patients with chronic obstructive pulmonary disease before and after the 30 days treatment with tiotropium bromide Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013